Antibodies Journal
Explore evitria’s Antibody Journal for in-depth articles on antibody engineering, CHO cell expression systems, and advancements in recombinant antibody production services.
Articles about Antibodies Journal (2)
-
Recombinant Protein Expression in Mammalian Cells: Techniques and Applications
There are several ways to produce recombinant proteins. In this article, we will have a look at some of them, and will focus on recombinant protein expression in mammalian cells.
-
Recombinant antibody expression – the process in detail
The expression of recombinant antibodies has opened entirely new possibilities in life sciences. In this article, we will take a more detailed look at this process.
-
Recombinant Antibody Production: Complete Guide
Recombinant antibody production is vital in drug development as well as for therapeutic and research purposes. In this article, we will discuss methods and benefits of recombinant antibody production.
-
Garbage In, Garbage Out: Why AI Antibody Discovery Needs Data Integrity
AI antibody discovery models are only as reliable as the data they train on. Learn why standardized CHO-native HTP production is the foundation of valid AI predictions.
-
HTP vs. Preclinical-Scale Antibody Production: When Should You Scale Up?
Understand the key differences between HTP and preclinical-scale antibody production, when to transition between stages, and why CHO consistency across both reduces downstream risk.
-
How Automation in HTP Antibody Production Reduces Batch Variation in CHO Expression
Batch-to-batch variation corrupts training data and derails lead selection. Learn how automated transient CHO expression eliminates it at every process step.
-
High-Throughput Antibody Production: A Guide to Workflows, Platforms, and Decision-Ready Data
Complete guide to High-Throughput Antibody Production: CHO-native workflow, developability screening, and decision-grade material in 4 weeks.
-
AAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody development
STOCKHOLM / 23 April 2026 – Biotech company AAX Biotech, a leading innovator in technologies for antibody-based therapies, today announced a partnership with evitria AG, an expert provider of antibody engineering and expression services, to enable the use of its Opti-mAb® technology in early antibody development workflows. AAX Biotech develops proprietary technologies, including Opti-mAb®, supporting […]
-
HEK293 vs. CHO for HTP Antibody Expression: Impact on Glycosylation and Folding
Choosing an expression host defines an antibody’s biological signature. While HEK293 is often used for convenience, it introduces significant risks in glycosylation and folding. By aligning HTP screening with CHO-native standards from the start, discovery teams eliminate host-switch leads are truly ready for clinical success.
-
Transient vs. Stable Expression in High-Throughput Antibody Screening: When to Switch
The choice between transient and stable expression defines the pace and precision of an antibody program. While transient systems provide the agility for high-throughput screening, stable cell lines offer the consistency required for clinical manufacturing. Understanding the technical triggers for this switch is essential for optimizing timelines and ensuring manufacturing success.
-
Physical Validation at Scale: How HTP Supports AI-Designed Antibody Discovery
AI accelerates antibody discovery, but physical validation remains essential to bridge the gap between digital design and biological reality. High-Throughput (HTP) platforms enable a ‘lab-in-the-loop’ approach, providing the manufacturing-relevant CHO data needed to refine predictive models and ensure that AI-generated candidates are truly developable from the earliest stage.
-
Fail Fast, Succeed Faster: The Role of Early Developability Assessment
Shifting developability assessment to the early discovery phase represents a strategic opportunity to eliminate high risk candidates before significant investment. By utilizing CHO based expression from the very first screening you ensure that early data is truly predictive of manufacturing success. This proactive approach de risks the journey from the bench to preclinical validation by identifying structural liabilities before they become costly failures.